Iron-oxide nanoparticle-integrated soft contact lenses: optical optimization, catalytic functionality, and biocompatibility
Abstract
Millions of people suffer from corneal infections and inflammatory conditions, and a contact lens that not only corrects vision but also continuously protects against microbes and inflammation could transform ocular therapeutics. Compared with plasmonic metal nanoparticles, such as silver or gold, iron oxide nanoparticles are well known for their biocompatibility, low toxicity, and low cost. To our knowledge, this work is the first to demonstrate the integration of iron oxide nanoparticles into commercial contact lenses. Nanoparticles were characterized using X-ray diffraction, X-ray photoelectron spectroscopy, scanning electron microscopy and transmission electron microscopy. Optical properties were assessed using UV-Vis spectroscopy and COMSOL simulations. Catalytic activity was evaluated by methylene blue degradation in the presence of H2O2. Lens's biocompatibility, anti-inflammatory and anti-bacterial properties were investigated using fibroblast cell viability assays and antibacterial testing. X-ray diffraction verified the structure with a lattice parameter of 8.37 Å, while XPS shows that the obtained nanoparticles (NPs) consisted of a mixture of both Fe3O4/γ-Fe2O3 NPs. SEM and transmission electron microscope confirmed that the NPs are uniformly dispersed and have an average size of ∼8 nm. UV-vis spectroscopy results showed significant optical transmission after embedding the NPs. The COMSOL simulation data indicated that smaller nanoparticle radii maintain high…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.